Home | All trials

[RDF data]
Trial NCT00617474

Resource URI: http://static.linkedct.org/resource/trials/NCT00617474
linkedct:arm_group <http://static.linkedct.org/resource/arm_group/20146>
linkedct:arm_group <http://static.linkedct.org/resource/arm_group/4908>
linkedct:brief_title The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group
linkedct:collaborator_agency <http://static.linkedct.org/resource/collabagency/7151>
linkedct:condition <http://static.linkedct.org/resource/condition/13204>
linkedct:criteria Inclusion Criteria: - Hb: >8 and <10 gr/dl - Age: >18 and <55 years - Cholesterol: <300 mg/dl - Triglyceride: <400 mg/dl - First Transplantation - Protocol of Immunosuppression: CSA + MMF + Prednisolone - Systolic BP: <14 - Diastolic BP: <9 Exclusion Criteria: - History of specified cardiac disease - Second Transplantation or more - Hb: <7gr/dl - The patient needs to infusion of blood - Evidence of local or systemic infection, at the time of EPO injection - Presence of ATN / DGF after transplantation - Presence of emergent hypertension - High risk patients ( Like; PRA>50%) - Past history of hypersensitivity
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers Accepts Healthy Volunteers
linkedct:eligibility_maximum_age 55 Years
linkedct:eligibility_minimum_age 18 Years
linkedct:end_date March 2009
linkedct:enrollment 50 (xsd:int)
linkedct:firstreceived_date February 6, 2008
linkedct:id NCT00617474
linkedct:intervention <http://static.linkedct.org/resource/intervention/60814>
linkedct:intervention <http://static.linkedct.org/resource/intervention/62095>
rdfs:label Trial NCT00617474
linkedct:lastchanged_date March 27, 2008
linkedct:lead_sponsor_agency Labbafinejhad Hospital
linkedct:nct_id NCT00617474
linkedct:number_of_arms 2 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group
linkedct:org_study_id L1386
linkedct:overall_status Not yet recruiting
linkedct:oversight <http://static.linkedct.org/resource/oversight/1388>
foaf:page <http://clinicaltrials.gov/show/NCT00617474>
linkedct:phase Phase 1
linkedct:primary_completion_date September 2008
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/66849>
linkedct:secondary_id 200786
linkedct:source Labbafinejhad Hospital
linkedct:start_date March 2008
linkedct:study_design Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
linkedct:study_type Interventional
linkedct:summary The study hypothesis is that erythropoietin usage after kidney transplantation, in early phase, can improve the outcome for patients and their graft increasing patient and graft survival.
rdf:type linkedct:trials
linkedct:verification_date March 2008